These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17942942)

  • 1. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice.
    Zaman F; Menendez-Benito V; Eriksson E; Chagin AS; Takigawa M; Fadeel B; Dantuma NP; Chrysis D; Sävendahl L
    Cancer Res; 2007 Oct; 67(20):10078-86. PubMed ID: 17942942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
    Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition: mechanism of action.
    DeMartino GN
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S5-9. PubMed ID: 19791423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition as a novel therapeutic target in human cancer.
    Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
    J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
    Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
    Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
    Yin D; Zhou H; Kumagai T; Liu G; Ong JM; Black KL; Koeffler HP
    Oncogene; 2005 Jan; 24(3):344-54. PubMed ID: 15531918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.
    Gopalan B; Shanker M; Scott A; Branch CD; Chada S; Ramesh R
    Cancer Gene Ther; 2008 Jan; 15(1):1-8. PubMed ID: 17828282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
    J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
    Van Herck JL; De Meyer GR; Martinet W; Bult H; Vrints CJ; Herman AG
    Basic Res Cardiol; 2010 Jan; 105(1):39-50. PubMed ID: 19693627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
    Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
    J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
    Baumann P; Müller K; Mandl-Weber S; Leban J; Doblhofer R; Ammendola A; Baumgartner R; Oduncu F; Schmidmaier R
    Br J Haematol; 2009 Mar; 144(6):875-86. PubMed ID: 19170678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
    Thorpe JA; Christian PA; Schwarze SR
    Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
    LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp72 controls bortezomib-induced HepG2 cell death via interaction with pro-apoptotic factors.
    Calvaruso G; Giuliano M; Portanova P; Pellerito O; Vento R; Tesoriere G
    Oncol Rep; 2007 Aug; 18(2):447-50. PubMed ID: 17611669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.